Quick Enquiry
Named Patient Medicine|Rare disease medicine whole saler|Orphan drug medicine whole saler|BE/BA studies medicine|US/japan/Europe approved medicine|US FDA /EMEA approved medicine


Reference Listed Drugs/RLDs Supplier in India

To market a medicinal product, manufacturing companies need to carry out a head-to-head comparison with its original counterpart, the Reference Listed Drugs (RLDs) or Reference Medicinal Products (RMPs). Referred to as Comparability Exercise, this process focuses on underlying both the parities between generic or biosimilar and reference medicinal products, as well as the disparities in their manufacturing approach. This is an imperative practice to bag authorization from regulatory bodies such as the FDA (Food and Drug Administration) and EMA (European Medicines Agency) to develop a generic medicine or biosimilar drug.
In other words, Reference Listed Drug (RLD) means a listed drug recognized by regulatory authorities like the FDA or EMA as a medicinal product upon which an applicant may rely in aspiring for approval of an Abbreviated New Drug Application (ANDA). A drug manufacturing company aspiring for approval to market a generic counterpart of a brand name drug must refer to the Reference Listed Drug (RLD) in its ANDA. By designating a single reference listed drug (RLD) as the norm to which all generic version products must be manifested to be bioequivalent, the regulatory authority (FDA) hopes to evade the probable significant contrast among generic medicinal products and their brand name alternatives/counterparts.
If you are searching for a reliable RLD sourcing company in India, and would you like to order reference listed drugs for clinical trials and analytical purposes in the most convenient way? IKRIS Pharma provides worldwide access to reference medicinal products (reference listed drugs/RLDs, comparator drugs) with complete service from sourcing to delivery. We can efficiently source RLD upon the requirements and inquiries given.

What IKRIS Offer:

  • Competitive sourcing of RLDs/comparator drugs from international pharmaceutical markets
  • Access to difficult-to-source reference products including restricted-use products and biologics
  • Worldwide network through secure and deep-rooted collaborations with international suppliers or wholesalers
  • Complete confidentiality
  • Complete conformity with current GDP directives
  • Leading logistics and suitable courier partners which allow us to efficiently get your RLDs to you on/ahead of time.
  • Consideration of particular customer requests, e.g. specific batch numbers or particular European Union countries
  • Comprehensive documentation package in order to meet pertinent regulatory needs

We understand to challenge of Reference Listed Drug/RLD sourcing as it requires multiple lots, shelf life, and desired quantities, and to overcome this complex challenge we have an extensive as well as strong network of multiple suppliers/distributors across the world. IKRIS Pharma Network can help to procure the required samples and the relevant deets in a quick and efficient way.


  • healthcare The Branded medicines typically are either synthetic (they are developed from a chemical procedure), or biological (they are developed from living sources). Synthetic brand-name medicines can be exactly replicated into more affordable generic versions..
  • Biosimilars Biologics: Medications made living organisms Biologics medicine includes medicines from living organisms, including animal cells and living organisms, like yeast and bacteria. That makes biologics different from conventional medications commonly made from chemicals. Unlike conventional medications, biologics cannot be made by following a chemical “recipe.” Because biologics generally come from living organisms. Thus, developing biologics can be more complicated than manufacturing conventional drugs..